Finally, we report that ZNF224 is significantly down-regulated in patients with BCR-ABL positive chronic phase-CML showing poor response or resistance to imatinib treatment as compared to high-responder patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.